Home・Lista de Ações・Roivant Sciences Ltd

Roivant Sciences Ltd

Fechado

SetorSaúde

36.47 0.3

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

35.65

Máximo

36.56

Indicadores-chave
By Trading Economics
Rendimento	-646M -291M
Vendas	-1.1M 1.4M
EPS	-0.45
Margem de lucro	-20,152.982
Funcionários	721
EBITDA	-743M -288M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+16.39% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	2.1B 26B
Abertura anterior	36.17
Fecho anterior	36.47

Sentimento de Notícias

By Acuity

50%

150 / 340 Ranking em Healthcare

Roivant Sciences Ltd Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de ago. de 2026, 23:01 UTC

Roivant Sciences Ltd. shares are lower in after-market trading, retracing from an earlier session high while remaining above the 20-day moving average.

21 de ago. de 2026, 19:31 UTC

Roivant Sciences is declining in Friday's session, with no specific news identified. The stock has seen unusually high trading volume today.

20 de ago. de 2026, 23:21 UTC

Roivant Sciences Ltd. shares are lower in after-market trading amid broader market pressures, including rising bond yields and concerns over high borrowing costs.

19 de ago. de 2026, 23:26 UTC

Roivant Sciences Ltd is seeing upward momentum in after-market trading, recovering from a prior dip and nearing the upper end of its one-month trading range.

18 de ago. de 2026, 23:01 UTC

Roivant Sciences Ltd shares are lower in after-market trading, declining notably after Tuesday's close amid rising U.S. Treasury yields and inflation concerns.

17 de ago. de 2026, 19:36 UTC

Roivant Sciences shares are roughly flat amid broader market declines. The bond market faces upward pressure on yields due to inflation concerns.

14 de ago. de 2026, 19:26 UTC

Roivant Sciences Ltd. remains near unchanged amid no specific news, fluctuating around flat levels during Friday's session. It is 4.29% above its 20-day moving average.

13 de ago. de 2026, 19:36 UTC

Roivant Sciences Ltd is trading modestly higher amid broader market dynamics. Initial jobless claims rose above expectations, indicating potential softness in the labor market.

12 de ago. de 2026, 22:11 UTC

Roivant Sciences shares are higher in after-market trading, driven by a positive market reaction to the July Consumer Price Index report.

11 de ago. de 2026, 21:01 UTC

Roivant Sciences Ltd shares are lower in after-market hours, continuing recent declines amid broader market volatility linked to U.S.-Iran relations.

10 de ago. de 2026, 23:02 UTC

Roivant Sciences Ltd shares are higher in after-market hours, trading above their 20-day moving average and near the upper end of their one-month range.

7 de ago. de 2026, 20:02 UTC

Event

News

Roivant Sciences Ltd shares are higher as HC Wainwright maintains a Buy rating and raises the price target to $41 amid positive developments in its product pipeline.

6 de ago. de 2026, 20:03 UTC

News

Event

Roivant Sciences reported a net loss of $290.6 million in Q1, exceeding expectations. Shares are higher despite pulling back from session highs earlier.

5 de ago. de 2026, 22:01 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting notable activity following Wednesday's close. The stock is positioned above its 20-day moving average.

4 de ago. de 2026, 20:02 UTC

Roivant Sciences is rising amid positive market sentiment and declining crude oil prices. Remarks from Treasury Secretary Scott Bessent also support the favorable environment.

3 de ago. de 2026, 20:06 UTC

Roivant Sciences Ltd shares are declining today, breaking a trend of higher closes. Broader market indices are up, but no specific news explains the drop.

31 de jul. de 2026, 20:02 UTC

Roivant Sciences Ltd shares are lower today amid significant declines in biotechnology stocks, breaking a trend of higher daily closes since Thursday.

30 de jul. de 2026, 23:46 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting a modest gain since Thursday's close. The stock fluctuated within a narrow range.

29 de jul. de 2026, 23:02 UTC

Roivant Sciences Ltd shares are lower in after-market hours amid broader market concerns and unusual volatility, with no specific company news identified.

28 de jul. de 2026, 23:06 UTC

Roivant Sciences Ltd shares are lower in after-market hours, continuing a trend of declines over the past three sessions without any specific news to explain the movement.

24 de jul. de 2026, 18:46 UTC

Roivant Sciences Ltd shares are trading higher, reflecting broader market dynamics amid a rebound in some sectors following a significant decline in oil prices.

23 de jul. de 2026, 20:06 UTC

Roivant Sciences Ltd is higher during Thursday's session, despite pulling back from an earlier session high. No specific news was identified for the movement.

22 de jul. de 2026, 22:26 UTC

Roivant Sciences Ltd shares are lower in after-market trading, with no specific news identified to explain the decline amid broader market volatility.

21 de jul. de 2026, 22:21 UTC

Roivant Sciences Ltd shares are lower in after-market hours, despite a broader market rebound following positive earnings from companies like General Motors and 3M.

20 de jul. de 2026, 16:36 UTC

Roivant Sciences Ltd. shares are lower today amid ongoing Middle East conflict affecting market sentiment and fluctuations in Brent crude prices.

Comparação entre Pares

Variação de preço

Roivant Sciences Ltd Previsão

Preço-alvo

By TipRanks

16.39% parte superior

Previsão para 12 meses

Média 42.25 USD 16.39%

Máximo 50 USD

Mínimo 37 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Roivant Sciences Ltd - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Roivant Sciences Ltd - Dist nos últimos 3 meses.

Sentimento

By Acuity

150 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.